Sunshine Biopharma Prices $6M Offering with 12 Million Units and Series C Warrants
Sunshine Biopharma priced a public offering of 12 million units at $0.50 per unit, raising approximately $6.0 million before expenses. Each unit comprises one share or a pre-funded warrant plus two Series C warrants exercisable at $0.50 for five years, with net proceeds allocated to general corporate purposes and working capital.
1. Public Offering Details
Sunshine Biopharma priced 12,000,000 common or pre-funded units at $0.50 each, generating gross proceeds of $6.0 million before placement agent fees and expenses. Each unit includes one share of common stock or one pre-funded warrant, plus two Series C warrants exercisable at $0.50 per share for five years, subject to adjustment.
2. Proceeds and Purpose
Net proceeds from the offering are intended to bolster the company’s working capital and support general corporate purposes, enhancing financial flexibility ahead of key operational milestones.
3. Pipeline and Operations
The company currently markets 60 generic prescription drugs in Canada with 12 additional launches planned for 2026, while advancing an mRNA-LNP therapeutic candidate targeting liver cancer and a small-molecule PLpro protease inhibitor for SARS-related coronavirus infections.